Drug data last refreshed 7h ago · AI intelligence enriched 1w ago
ORAP is an oral tablet medication approved in 1984 as a New Drug Application (NDA) sponsored by Teva. The drug's specific indication, mechanism of action, and pharmacologic class are not documented in available data.
With LOE approaching and minimal linked jobs, this product is likely in maintenance or wind-down mode, indicating limited team expansion opportunities.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Study to Demonstrate Pharmacokinetic and Pharmacodynamic Similarity Between NKF-INS(A), US-NovoLog®, and EU-NovoRapid®
Sulforaphane Use to Effect Inflammatory and Metabolic Changes in Virally Suppressed HIV Patients
Efficacy and Safety of GP40071 Compared to NovoRapid® Penfill® in Type 1 Diabetes Mellitus Patients
A Study to Compare Pharmacokinetics and Pharmacodynamics of Insulin Aspart to NovoRapid® Penfill® in Healthy Subjects
Vorapaxar and Lower Extremity Bypass Grafts
Worked on ORAP at Teva? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
ORAP has zero linked job openings and appears to be a legacy product with minimal ongoing team support. Career growth on this asset is severely constrained by its LOE status and lack of active development.